E. Spek

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

P. Sonneveld, A. Waage, N. Abildgaard, 2018, Haematologica.

Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia

M. Dimopoulos, C. Buske, R. Hájek, 2015 .

n ew developments in the treatment of patients with multiple myeloma

M. Minnema, E. V. D. Spek, E. Spek, 2010 .

Targeting the mevalonate pathway in multiple myeloma

E. V. D. Spek, E. Spek, 2010 .

Comment to: Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403

R. Griend, E. Spek, 2008 .